Company Overview - Dentsply Sirona focuses on innovation in dental care, digital dentistry, and consumable solutions, which supports recurring revenue streams and customer retention [1] - The company is a leading global manufacturer of dental products and technologies, employing approximately 14,000 people and offering a diverse range of products [1] Market Position and Revenue Generation - Dentsply Sirona serves dental practitioners, specialists, dental laboratories, and healthcare providers globally, primarily generating revenue through the sale of dental equipment and consumables [2] - The company leverages both recurring product sales and technology-driven solutions to enhance its revenue [2] Recent Financial Performance - In 2025, Dentsply Sirona reported sales of $3.4 billion, a decrease from $3.8 billion in the previous year, and incurred a net loss of $598 million due to a $650 million goodwill impairment charge [7] - The company's free cash flow (FCF) declined to $104 million in 2025 from $281 million in the prior year, raising concerns about its ability to sustain its dividend, which currently yields over 5% [7] Investment Insights - Gregory T. Lucier, a Board member, purchased 15,000 shares at an average price of $12.45, indicating a bullish outlook on the stock and belief in its attractive valuation [5][6] - The price-to-sales ratio of 0.64 for Dentsply Sirona shares is near a low for the past year, suggesting a compelling valuation for potential investors [6] - Lucier's substantial holdings, now totaling nearly 25 million shares, imply confidence in the company's ability to maintain its dividend [8]

Question-and-Answer SessionMichael ChernyLeerink Partners LLC, Research Division Dan, we were talking a little bit before, and one of the things I said I admired is your bluntness. You came in as CEO, and you're very direct with us about your thought process on the business and the focus on what you've termed the return to growth opportunity. How are you tracking yourself and for the organization, the quarter-by-quarter progress? I mean, I know it's not quarter-quarter for us, week by week for sure for you ...

Summary of DENTSPLY SIRONA Conference Call Company Overview - **Company**: DENTSPLY SIRONA (NasdaqGS: XRAY) - **Date**: March 10, 2026 - **Context**: Discussion at the Leerink Partners Global Healthcare Conference Key Points Return to Growth Strategy - The CEO emphasized a focus on a "return to growth opportunity" and the urgency in tracking progress on a day-to-day basis rather than quarterly [4][10] - Metrics for success include engaging and expanding dealer relationships, which are crucial for the U.S. CTS business recovery [10][11] Dealer Engagement and Simplification - New leadership among dealers has allowed for a fresh start in relationships, focusing on simplicity in deal structures to enhance volume and efficiency [13][14] - The dropship model is being implemented to streamline inventory management and improve cash flow, reducing the burden of excess inventory on dealers [16][19] R&D Investments - Incremental R&D spending is being allocated to enhance product vitality across various verticals, including endodontics, orthodontics, and implants [22][23] - The focus is on leveraging the DS Core platform to accelerate software development and improve product offerings [22][28] Market Dynamics and Product Penetration - The CEO noted that the market appears stable, but the company's challenges are internal rather than market-driven [50][51] - EMEA is identified as a strong market for implants, while Asia Pacific holds significant growth potential [68][69] Clinical Education and Sales Force - Investments in clinical education and sales force training are prioritized to enhance product awareness and improve sales execution [42][49] - The CEO plans to establish a CEO advisory board with dentists to refine strategies and enhance clinical education [41][42] AI and Technology Integration - AI is being explored both as an external tool for customer service and as an internal efficiency tool to streamline operations [63][66] - The company is looking to modernize its software and improve internal processes using AI technologies [66] Orthodontics and SureSmile - The SureSmile platform is being positioned to regain market share, with a focus on modernizing software and enhancing clinical outcomes [91][92] - The CEO acknowledged the need to rebuild trust with orthodontists after previous missteps [101][102] Financial Outlook - The company is undergoing restructuring, which may lead to EPS pressures in the first half of the year, with expectations for improvement in the second half [108][109] - The focus is on long-term growth rather than short-term gains, with plans to strengthen cash flow and shareholder value [109][110] Conclusion - DENTSPLY SIRONA is actively working on a comprehensive strategy to return to growth through dealer engagement, R&D investments, and market penetration, while addressing internal challenges and leveraging technology for future success [4][50][108]

Core Insights - Dentsply Sirona and Siemens Healthineers have received FDA clearance for the MAGNETOM Free.Max Dental Edition, the first dental-dedicated MRI system, following a successful clinical trial that validates its potential across various dental specialties [1][2]. Group 1: Clinical Trial Findings - The clinical trial confirmed the ddMRI system's significant potential in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, highlighting its specialized features tailored for dental professionals [2][3]. - The system offers a dental-specific field of view, utilizing a dedicated dental coil and specialized software to focus exclusively on dental structures, ensuring no brain tissue visibility [2]. - The average workflow time for the ddMRI system is under 20 minutes, enhancing efficiency in clinical settings [2]. Group 2: Technological Advancements - MAGNETOM Free.Max Dental Edition provides non-ionizing imaging capabilities, allowing for better insights into dental structures without the risks associated with ionizing radiation [4][5]. - The system can differentiate active inflammation from healthy and scar tissue and assess tooth pulp vitality non-invasively, supporting chairside testing [3][4]. - The advanced soft tissue contrast of ddMRI complements existing imaging solutions like intraoral, panoramic, and CBCT imaging, addressing critical diagnostic questions [5][6]. Group 3: Market Position and Future Prospects - The ddMRI system is primarily intended for hospitals, large clinics, and universities, aiming to enhance dentomaxillofacial diagnostics [6]. - Dentsply Sirona's President & CEO emphasized the significance of this innovation in advancing diagnostic capabilities within the dental field [7]. - Siemens Healthineers expressed commitment to expanding the clinical impact of MRI technology, indicating a promising future for ddMRI in dental practices [8]. Group 4: Training and Education - An advanced hands-on training program for clinicians interested in ddMRI will take place in April 2026 at the University of Minnesota, covering imaging protocols and clinical procedures [9]. - The upcoming American Dental Education Association (ADEA) Annual Session will feature Dentsply Sirona's booth, providing further insights into the ddMRI system [11].

Fund Performance - Ariel Fund delivered a +3.22% return in Q4 2025, in line with Russell 2500 Value Index (+3.15%) and Russell 2000 Value Index (+3.26%) [1] - For the trailing one-year period, the Fund advanced 14.15%, outperforming Russell 2500 Value Index (+12.73%) and Russell 2000 Value Index (+12.59%) [1] - The Fund's 5- and 10-year average annual returns were +9.36% and +9.51%, respectively [1] Market Conditions - Performance attributed to resilient corporate earnings, easing inflation, and rising expectations for accommodative monetary policy [1] - Continued enthusiasm around artificial intelligence and cloud infrastructure supported markets, although gains were concentrated in a narrow group of large-cap stocks [1] Outlook and Strategy - The firm maintains a measured and cautious outlook for 2026, citing geopolitical risks, fiscal constraints, labor market dynamics, and elevated market concentration as potential volatility sources [1] - Management reaffirmed a long-term, bottom-up approach, emphasizing strong balance sheets, durable fundamentals, and valuation discipline [1] Company Focus: DENTSPLY SIRONA Inc. - DENTSPLY SIRONA Inc. is a dental equipment and consumables manufacturer with a one-month return of -10.25% and a market capitalization of approximately $2.47 billion [2] - The company has faced challenges in its core capital equipment business due to lower-cost technology alternatives, but the dental market is viewed favorably for its steady growth and lower reimbursement risk [3] - Management is executing a strategic reset focused on innovative product development, operational efficiencies, and emerging market growth to strengthen competitive positioning [3]

Core Viewpoint - Dentsply Sirona will participate in the Leerink Partners Global Healthcare Conference on March 10, 2026, at 10:00 a.m. EST, providing an opportunity for investors to gain insights into the company's operations and future strategies [1]. Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies globally, with over a century of innovation in the dental industry [3]. - The company develops, manufactures, and markets a comprehensive range of dental and oral health products, as well as other consumable medical devices, under a strong portfolio of world-class brands [3]. - Dentsply Sirona's innovative products aim to provide high-quality, effective, and connected solutions to enhance patient care and ensure safer dental practices [3]. - The company is headquartered in Charlotte, North Carolina, and its shares are listed on Nasdaq under the symbol XRAY [3].

Core Insights - Dentsply International's international operations are crucial for assessing its financial strength and growth potential, especially given the interconnected global economy [2][3] Group 1: Financial Performance - The company's total revenue for the quarter ending December 2025 was $961 million, reflecting a 6.2% increase from the same quarter last year [4] - Revenue from Europe was $428 million, accounting for 44.5% of total revenue, surpassing the consensus estimate of $420.19 million by 1.86% [5] - The Rest of World segment generated $237 million, representing 24.7% of total revenue, which was a decline of 2.42% from the projected $242.88 million [6] Group 2: Future Revenue Expectations - Analysts predict Dentsply will report total revenue of $868.58 million in the current fiscal quarter, indicating a 1.2% decline from the prior year [7] - For the full year, total revenue is expected to reach $3.57 billion, down 3.1% from the previous year, with Europe and Rest of World projected to contribute $1.61 billion and $929.51 million, respectively [8] Group 3: Market Trends and Stock Performance - The reliance on international markets presents both opportunities and challenges for Dentsply, making it essential to monitor international revenue trends for future projections [9] - Over the past four weeks, Dentsply's stock has increased by 17.2%, outperforming the S&P 500, which declined by 1.3% [14] - In the last three months, the company's shares rose by 28.9%, compared to a 1% increase in the S&P 500 [14]

Core Insights - During market turbulence, investors often seek dividend-yielding stocks, which typically have high free cash flows and offer substantial dividends to shareholders [1] Group 1: High-Yielding Stocks in Health Care Sector - The article highlights three high-yielding stocks in the health care sector: Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc [2][3]

Core Viewpoint - Dentsply Sirona Inc. (NASDAQ:XRAY) experienced a significant rebound in stock price due to the announcement of a share repurchase program, despite the termination of its quarterly dividends [1][9]. Financial Performance - The company reported an attributable net loss of $598 million for the previous year, which is a 34% improvement from a net loss of $910 million in 2024 [3]. - Net sales decreased by 3% to $3.68 billion from $3.79 billion [3]. - In the fourth quarter, the attributable net loss narrowed by 66% to $146 million from $430 million year-on-year, while net sales increased by 6.2% to $961 million from $905 million [4]. Corporate Strategy - Dentsply Sirona initiated a new capital allocation strategy as part of its corporate restructuring, eliminating quarterly dividends to focus on share buybacks and debt retirement [2][5]. - The restructuring aims to streamline operations, improve efficiency, and support a more competitive cost structure, with the goal of driving sustained, profitable growth and delivering long-term value for shareholders [5]. Future Outlook - For the current year, Dentsply Sirona expects net sales to decline by 2% to 5%, projecting a range of $3.5 billion to $3.6 billion [6]. - Adjusted EPS is targeted between $1.40 and $1.50 [6].

Core Insights - DENTSPLY SIRONA is implementing a 24-month "Return-to-Growth" action plan focused on customer engagement, innovation, execution improvements, and capital allocation changes following organizational changes in 2025 [3] Financial Performance - The company reported fourth-quarter revenue of $961 million, reflecting a 6.2% increase and 2.5% growth in constant currency, aided by a 370-basis-point foreign exchange tailwind [4] - Adjusted EBITDA margin for the quarter was 14.1%, a decrease of 10 basis points year over year, impacted by a 300-basis-point decline in gross profit due to lower volume, sales mix, and tariffs, with a $15 million tariff impact noted [5] - A non-cash goodwill impairment charge of $144 million was recorded, primarily due to tariffs and volume declines, alongside a full-year sales total of $3.68 billion [7] Cash Flow and Dividends - Operating cash flow for the quarter was $101 million, with free cash flow at $60 million, and the company ended the quarter with $326 million in cash and cash equivalents [6] - The company paid $32 million in dividends during the quarter, totaling $128 million for the full year of 2025, but has eliminated dividends to prioritize debt reduction and share repurchases [7] Future Guidance - For 2026, management projects sales between $3.5 billion and $3.6 billion, representing a decline of 3% to 1% operationally, with adjusted EPS expected to be between $1.40 and $1.50 [7]